Synopsis
Highlights
History
Business
Property
Subsidiaries
Long term debt
Capital stock
Earnings estimates
Business segments
Download
Printer Friendly
|
|||||||||||||||||||||||||||||
Business Summary
AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in pharmaceutical business focusing on the research, development, manufacturing and commercialization of prescription medicines. Co. is focused on its therapy areas: Oncology, which provides Tagrisso (osimertinib) for lung cancer; BioPharmaceuticals, which provides Farxiga/ Forxiga (dapagliflozin) for Type-2 diabetes, heart failure with reduced ejection fraction and chronic kidney disease; and Rare Disease, which provides Soliris (eculizumab) for paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, generalised myasthenia gravis and neuromyelitis optica spectrum disorder.Pricing Summary
Time Period
| Yesterday | 5 Days | 30 Days | |
|---|---|---|---|
| Close | 77.47 | 77.91 | 83.00 |
| Volume | 5,186,773.00 | 3,334,445.00 | 7,754,294.00 |
| 52 Week High/Low : | N/A - N/A | ||
| % Price Change (100 Days) : | -0.91 | ||
| 200-Day Moving Avg. : | 77.33 | ||
Company News
Corporate Events
Key Executives
| Age | ||
|---|---|---|
| Chief Executive Officer | 61 | |
| Chief Financial Officer | ||
| Chief Strategy Officer | ||
| Chief Human Resources Officer,General Counsel,Chief Compliance Officer | ||
| Executive Vice President | ||
Key Financials
(In USD as of 06/30/2024)| Income Statement | |
|---|---|
| Revenue | 49,133m |
| Net Income | 6,440m |
| EPS - Net Income - Diluted | 4.13 |
| Balance Sheet | |
| Total Assets | 104,340m |
| Total Liabilities | 64,828m |
| Shareholders' Equity | 39,512m |
| Total Assets per Share | 67.30 |
| Net Assets per Share | 25.49 |
| Cash Flows | |